2026 Douglas B. Johnson: Medicine Researcher – H-Index, Publications & Awards

Discipline name	D-Index	World Ranking	Current World Ranking	National Ranking	Current National Ranking	Publications	Citations
Medicine	100	8154	7665	4228	3915	383	49054

Overview

Douglas B. Johnson is affiliated with Vanderbilt University Medical Center in the United States. Their research primarily focuses on Medicine, with a specialization in Oncology, Molecular Biology, Immunology, Pulmonary and Respiratory Medicine, and Epidemiology.

Their scientific contributions prominently cover key topics such as:

Cancer Immunotherapy and Biomarkers
CAR-T cell therapy research
Melanoma and MAPK Pathways
Immunotherapy and Immune Responses
Cutaneous Melanoma Detection and Management
Colorectal Cancer Treatments and Studies
Brain Metastases and Treatment

Douglas B. Johnson has published extensively in well-known venues. The most frequent publication platforms include:

Journal of Clinical Oncology
Journal for ImmunoTherapy of Cancer
European Journal of Cancer
Annals of Oncology
The Oncologist

Coauthorship is a significant aspect of their work, collaborating repeatedly with several researchers:

Georgina V. Long
Alexander M. Menzies
Matteo S. Carlino
Ryan J. Sullivan
Justin M. Balko

Recent papers authored or coauthored by them include:

Immune-checkpoint inhibitors: long-term implications of toxicity, 2022, Nature Reviews Clinical Oncology
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events, 2021, Journal for ImmunoTherapy of Cancer
Accuracy and Reliability of Chatbot Responses to Physician Questions, 2023, JAMA Network Open
Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI: A Multicenter Study, 2020, Journal of the American Society of Nephrology
Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma, 2020, Cancer Cell

Best Publications

Genomic and transcriptomic features of response to anti-pd-1 therapy in metastatic melanoma

Willy Hugo;Jesse M. Zaretsky;Lu Sun;Chunying Song

3025
Citations
Fulminant Myocarditis with Combination Immune Checkpoint Blockade

Douglas B. Johnson;Justin M. Balko;Margaret L. Compton;Spyridon Chalkias

2293
Citations
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis

Daniel Y. Wang;Joe Elie Salem;Joe Elie Salem;Justine V. Cohen;Sunandana Chandra

2062
Citations
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.

Nicole M. Kuderer;Toni K. Choueiri;Dimpy P. Shah;Yu Shyr

1776
Citations
Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma

Mark B. Faries;John F. Thompson;Alistair J. Cochran;Robert H. Andtbacka

1339
Citations
Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data

Francesca Finotello;Clemens Mayer;Christina Plattner;Gerhard Laschober

1075
Citations
Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy.

Hubing Shi;Willy Hugo;Xiangju Kong;Aayoung Hong

1042
Citations
Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study.

Joe-Elie Salem;Joe-Elie Salem;Ali Manouchehri;Melissa Moey;Bénédicte Lebrun-Vignes

930
Citations
Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group Part 2 TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non–Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors

Shona Hendry;Roberto Salgado;Thomas Gevaert;Prudence A. Russell;Prudence A. Russell

897
Citations
Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors.

Satya Das;Douglas B. Johnson

849
Citations
Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma in Situ, Metastatic Tumor Deposits and Areas for Further Research

Shona Hendry;Roberto Salgado;Thomas Gevaert;Prudence A. Russell;Prudence A. Russell

800
Citations
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab

Alexander M. Menzies;Alexander M. Menzies;D. B. Johnson;S. Ramanujam;V. G. Atkinson

785
Citations
Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis

Javid J. Moslehi;Joe Elie Salem;Jeffrey A. Sosman;Bénédicte Lebrun-Vignes

769
Citations
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders

Douglas B. Johnson;Ryan J. Sullivan;Patrick A. Ott;Matteo S. Carlino

688
Citations
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis

Jennifer L. McQuade;Carrie R. Daniel;Kenneth R. Hess;Carmen Mak

667
Citations
Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade: A Systematic Review and Meta-analysis

Steve Lu;Julie E. Stein;David L. Rimm;Daphne W. Wang

650
Citations
Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance

Willy Hugo;Hubing Shi;Lu Sun;Marco Piva

615
Citations
Endosomolytic Polymersomes Increase the Activity of Cyclic Dinucleotide STING Agonists to Enhance Cancer Immunotherapy

Daniel Shae;Kyle W. Becker;Plamen Christov;Dong Soo Yun

527
Citations
Society for immunotherapy of cancer (sitc) clinical practice guideline on immune checkpoint inhibitor-related adverse events

Julie R. Brahmer;Hamzah Abu-Sbeih;Paolo Antonio Ascierto;Jill Brufsky

521
Citations
Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy

Douglas B. Johnson;Monica V. Estrada;Roberto Salgado;Violeta Sanchez

506
Citations

Frequent Co-Authors

Jeffrey A. Sosman Northwestern University

Georgina V. Long University of Sydney

Alexander M. Menzies University of Sydney

Justin M. Balko Vanderbilt University Medical Center

Ryan J. Sullivan Harvard University

Matteo S. Carlino University of Sydney

Javid Moslehi University of California, San Francisco

Igor Puzanov Roswell Park Cancer Institute

Antoni Ribas University of California, Los Angeles

Keith T. Flaherty Harvard University

External Links

Personal website of Douglas B. Johnson

If you think any of the details on this page are incorrect, let us know.

Related Online Degrees & Career Pathways

The pathway to a medical career in the USA can be both rewarding and diverse. For those interested in advanced nursing roles, programs such as adn to fnp (Associate Degree in Nursing to Family Nurse Practitioner) offer a flexible route for working nurses to earn graduate-level credentials online.

Nutrition also plays a crucial role in healthcare. Earning a nutritionist online degree can open doors to positions in wellness, dietetics, and preventive care, empowering professionals to guide patients toward healthier lifestyles.

If you are seeking a leadership or administrative position in healthcare without pausing your career, discovering whats the best online mha program for working adults can help you gain managerial skills and industry credentials through recognized, flexible online programs.

In addition, options like rn to bsn programs without clinicals enable nurses to advance their education without the need for in-person clinicals, making it easier to grow professionally while maintaining work and life commitments.